Clinical Trial Update: Open-Label Study Assessing The Safety, Immunogenicity and Dose Response of IC47 [Phase 1]

View source ↗

Summary

Phase 1 open-label study evaluating safety, immunogenicity, and dose response of IC47 in pneumococcal infections; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infections

Drugs mentioned

• IC47

Snippet

Sponsor: Valneva Austria GmbH | Conditions: Pneumococcal Infections | Phase 1 | Status: COMPLETED